The purpose of the study is to understand how a single dose of psilocybin affects brain activity related to cognitive control, which is the brain’s ability to manage thoughts and actions, in patients with CNEP. This will be assessed using a technique called MRI (Magnetic Resonance Imaging), which allows researchers to see detailed images of the brain. Participants will undergo an emotional task known as the Go-No Go task, which helps measure cognitive control, before and after receiving psilocybin.

During the study, participants will receive a single dose of psilocybin in capsule form. Brain activity will be monitored before and after the treatment using MRI scans. The study will also track changes in the frequency of seizures and other related symptoms over a period of time. This research aims to provide insights into how psilocybin might influence brain function and potentially help manage symptoms in people with psychogenic non-epileptic seizures.

The purpose of this study is to find out if MC-1 works well for long-term treatment of patients who have confirmed PNPO deficiency. Patients taking part in the study will receive MC-1 tablets by mouth over a period of up to one year. The study will look at whether this treatment helps control seizures and reduces the risk of death compared to patients who do not receive any treatment with pyridoxal phosphate. The study will also track how often seizures occur during the treatment period.

During the study, patients will take MC-1 tablets multiple times daily, similar to how they may have been taking other forms of this vitamin before. The treatment can last up to 52 weeks, with a maximum daily dose of 3 grams. The study is designed for patients aged 2 years and older who have had their condition confirmed through genetic testing and whose seizures are usually controlled with oral treatment.

The main goal of the study is to determine if a single dose of Staccato Alprazolam can stop a seizure within 90 seconds and prevent any more seizures for up to two hours. Participants will be randomly assigned to receive either the Staccato Alprazolam or a placebo. The study will take place over a period of time, during which participants will be monitored to see how they respond to the treatment. The study will also look at how long it takes for the seizure to stop after taking the medication and whether there are any side effects related to breathing.

Participants will be involved in the study as outpatients, meaning they will not need to stay in a hospital. The study aims to provide valuable information on whether Staccato Alprazolam is a safe and effective option for treating long seizures in both children and adults. The results could help improve treatment options for those who experience these types of seizures.

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato® alprazolam. Participants in the study will use the inhalation device to take the medication when they experience a seizure. The study will monitor how well participants tolerate the medication over time and will track any side effects that may occur. Some participants will receive a placebo, which looks like the medication but does not contain the active substance.

Throughout the study, researchers will collect information on the frequency of any side effects and how often these side effects lead to participants stopping the study. The study will also look at how successful the treatment is in managing seizures within the first year and whether there are any breathing-related side effects. This information will help determine if Staccato® alprazolam is a safe and effective treatment option for managing prolonged seizures in both children and adults.